Lisata Therapeutics (NASDAQ:LSTA) Stock Rating Reaffirmed by HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 316.67% from the stock’s previous close.

Lisata Therapeutics Trading Up 3.9 %

Shares of Lisata Therapeutics stock opened at $3.60 on Friday. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $2.92. Lisata Therapeutics has a 52 week low of $1.95 and a 52 week high of $4.48. The stock has a market cap of $29.91 million, a PE ratio of -1.46 and a beta of 1.13.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, equities analysts predict that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC boosted its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 269,839 shares of the company’s stock after buying an additional 26,000 shares during the period. Lisata Therapeutics comprises 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 24th largest holding. BML Capital Management LLC owned about 3.31% of Lisata Therapeutics worth $737,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.